Related references
Note: Only part of the references are listed.Pharmacokinetics and Tolerability of Intravenous Sulbactam-Durlobactam with Imipenem-Cilastatin in Hospitalized Adults with Complicated Urinary Tract Infections, Including Acute Pyelonephritis
Olexiy Sagan et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Safety, Pharmacokinetics, and Drug-Drug Interaction Potential of Intravenous Durlobactam, a β-Lactamase Inhibitor, in Healthy Subjects
Jason D. Lickliter et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii
Harald Seifert et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Targeting Multidrug-Resistant Acinetobacter spp.: Sulbactam and the Diazabicyclooctenone β-Lactamase Inhibitor ETX2514 as a Novel Therapeutic Agent
Melissa D. Barnes et al.
MBIO (2019)
Pharmacokinetics, Safety, and Tolerability of Intravenous Durlobactam and Sulbactam in Subjects with Renal Impairment and Healthy Matched Control Subjects
John O'Donnell et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Torsades de pointes and QT prolongation Associations with Antibiotics: A Pharmacovigilance Study of the FDA Adverse Event Reporting System
Chengwen Teng et al.
INTERNATIONAL JOURNAL OF MEDICAL SCIENCES (2019)
Scientific white paper on concentration-QTc modeling
Christine Garnett et al.
JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS (2018)
Frequency and Mechanism of Spontaneous Resistance to Sulbactam Combined with the Novel β-Lactamase Inhibitor ETX2514 in Clinical Isolates of Acinetobacter baumannii
Sarah M. McLeod et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Reversibility of Covalent, Broad-Spectrum Serine β-Lactamase Inhibition by the Diazabicyclooctenone ETX2514
Adam B. Shapiro et al.
ACS INFECTIOUS DISEASES (2017)
ETX2514 is a broad-spectrum β-lactamase inhibitor for the treatment of drug-resistant Gram-negative bacteria including Acinetobacter baumannii
Thomas F. Durand-Reville et al.
NATURE MICROBIOLOGY (2017)
Implications of the IQ-CSRC Prospective Study: Time to Revise ICH E14
Borje Darpo et al.
DRUG SAFETY (2015)
The Power of Phase I Studies to Detect Clinical Relevant QTc Prolongation: A Resampling Simulation Study
Georg Ferber et al.
BIOMED RESEARCH INTERNATIONAL (2015)
Antibiotic-induced Cardiac Arrhythmias
Elsayed Abo-Salem et al.
CARDIOVASCULAR THERAPEUTICS (2014)
Antimicrobials and the Risk of Torsades de Pointes The Contribution from Data Mining of the US FDA Adverse Event Reporting System
Elisabetta Poluzzi et al.
DRUG SAFETY (2010)
Long-QT syndrome
Dan M. Roden
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Share Paper
